PEPGEN INC. Lease, Cost
PEPGEN INC. (PEPG) reported Lease, Cost of $5.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-04
- PEPGEN INC. lease, cost for the quarter ending 2023-12-31 was $1.22M, a 248.86% increase year-over-year.
- PEPGEN INC. lease, cost for the quarter ending 2023-09-30 was $1.21M, a 226.76% increase year-over-year.
- PEPGEN INC. lease, cost for the quarter ending 2023-06-30 was $1.23M, a 377.82% increase year-over-year.
- PEPGEN INC. lease, cost for the quarter ending 2023-03-31 was $1.24M, a 291.48% increase year-over-year.
- PEPGEN INC. lease, cost for fiscal 2025 was $5.20M, a 8.98% decline from fiscal 2024.
- PEPGEN INC. lease, cost for fiscal 2024 was $5.71M, a 14.72% increase from fiscal 2023.
- PEPGEN INC. lease, cost for fiscal 2023 was $4.98M, a 284.85% increase from fiscal 2022.
- PEPGEN INC. lease, cost for fiscal 2022 was $1.29M, a 148.85% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.20M 10-K · filed 2026-03-04 | |||
| 2024-12-31 | $5.71M 10-K · filed 2026-03-04 | |||
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $2.43M derived: sum of 2 quarters · filed 2025-02-24 | $3.66M derived: sum of 3 quarters · filed 2025-02-24 | $4.98M 10-K · filed 2025-02-24 |
| 2023-09-30 | $1.21M 10-Q · filed 2023-11-08 | $2.44M derived: sum of 2 quarters · filed 2023-11-08 | $3.76M 10-Q · filed 2023-11-08 | $4.03M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $1.23M 10-Q · filed 2023-08-08 | $2.60M 10-Q · filed 2023-08-08 | $2.82M derived: sum of 3 quarters · filed 2024-03-29 | $3.19M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $1.24M 10-Q · filed 2023-05-11 | $1.59M derived: sum of 2 quarters · filed 2024-03-29 | $1.96M derived: sum of 3 quarters · filed 2024-03-29 | $2.22M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $350.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $720.00K derived: sum of 2 quarters · filed 2024-03-29 | $977.00K derived: sum of 3 quarters · filed 2024-03-29 | $1.29M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $370.00K 10-Q · filed 2023-11-08 | $627.00K derived: sum of 2 quarters · filed 2023-11-08 | $944.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $257.00K 10-Q · filed 2023-08-08 | $574.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $317.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $520.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |